TRACON PHARMS INC (TCON)
TCON moved a median of -0.63% 30 minutes after news, and -3.00% by the close. How TCON actually reacts to news — the realized, point-in-time move the market made, measured across 81 labeled events over the last three years with zero look-ahead.
TCON’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 21% | 81 |
| 30-min | -0.63% | 16% | 81 |
| 60-min | -2.28% | 16% | 81 |
| to close | -3.00% | 16% | 81 |
| Middle 50% of TCON reactions | -13.79% to 0.00% |
|---|---|
| Median reaction (30-min) | -0.63% |
| Measured reactions | 81 |
Half of all TRACON PHARMS INC news events land between -13.79% and +0.00% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TCON moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TCON's baseline. Nothing else.
Recent TCON events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Tracon Pharmaceuticals, | SEC filing · Form 15-12G | SEC EDGAR | +0.00% | -41.67% | |
| Form EFFECT Tracon Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -29.45% | |
| Form POS AM Tracon Pharmaceuticals, | SEC filing · Form POS | SEC EDGAR | +0.00% | -3.00% | |
| Form RW Tracon Pharmaceuticals, | SEC filing · Form RW | SEC EDGAR | +0.00% | -3.00% | |
| Form S-8 POS Tracon Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -3.00% | |
| Form DEFA14A Tracon Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | +9.62% | |
| Form 8-K Tracon Pharmaceuticals, For: Oct 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.28% | |
| Form DEF 14A Tracon Pharmaceuticals, For: Oct 11 | SEC filing · Form DEF | SEC EDGAR | -49.08% | -38.90% | |
| Form DEFA14A Tracon Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -49.08% | -38.90% | |
| Form 10-Q Tracon Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +25.56% | |
| Form PRE 14A Tracon Pharmaceuticals, For: Aug 09 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Tracon Pharmaceuticals, For: Jul 26 | SEC filing · Form 8-K | SEC EDGAR | -74.16% | -84.50% | |
| TRACON Pharmaceuticals Announces it Will Wind Down Operations | Press release | GlobeNewswire | -74.16% | -84.50% | |
| Form 8-K Tracon Pharmaceuticals, For: Jul 12 | SEC filing · Form 8-K | SEC EDGAR | +8.33% | +5.03% | |
| Form 8-K Tracon Pharmaceuticals, For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | -1.57% | -12.60% | |
| TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform | Press release | GlobeNewswire | -1.57% | -12.60% | |
| Form 8-K Tracon Pharmaceuticals, For: Jun 19 | SEC filing · Form 8-K | SEC EDGAR | +2.43% | +0.82% | |
| Form 8-K Tracon Pharmaceuticals, For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +7.79% | +43.89% | |
| TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients | Press release | GlobeNewswire | +1.82% | -1.82% | |
| Form 10-Q Tracon Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +3.19% | +1.25% | |
| Form 8-K Tracon Pharmaceuticals, For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +3.19% | +1.25% | |
| TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +3.19% | +1.25% | |
| Form 8-K Tracon Pharmaceuticals, For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -0.98% | +1.00% | |
| TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024 | Press release | GlobeNewswire | +0.00% | -2.76% | |
| Form 8-K Tracon Pharmaceuticals, For: Apr 12 | SEC filing · Form 8-K | SEC EDGAR | +3.49% | -16.28% | |
| Form S-1 Tracon Pharmaceuticals, | SEC filing · Form S-1 | SEC EDGAR | +3.49% | -16.28% | |
| Form 8-K Tracon Pharmaceuticals, For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | -4.98% | +0.00% | |
| Form 8-K Tracon Pharmaceuticals, For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | -1.07% | -20.69% | |
| TRACON Pharmaceuticals Announces Reverse Stock Split | Press release | GlobeNewswire | -1.07% | -20.69% | |
| Form 8-K Tracon Pharmaceuticals, For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | -20.45% | -44.57% | |
| TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned | Press release | GlobeNewswire | -20.45% | -44.57% | |
| Form S-8 Tracon Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +2.76% | +8.38% | |
| Form 10-K Tracon Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.30% | -1.50% | |
| Form 8-K Tracon Pharmaceuticals, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -1.30% | -1.50% | |
| TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.30% | -1.50% | |
| TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 | Press release | GlobeNewswire | +3.45% | +4.02% | |
| TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial | Press release | GlobeNewswire | -1.47% | -13.84% | |
| Form 8-K Tracon Pharmaceuticals, For: Dec 13 | SEC filing · Form 8-K | SEC EDGAR | -1.47% | -13.84% | |
| Form 8-K Tracon Pharmaceuticals, For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | -7.86% | -10.31% | |
| Form 8-K Tracon Pharmaceuticals, For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | -8.72% | -11.03% | |
| TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment | Press release | GlobeNewswire | -8.72% | -11.03% | |
| Form 10-Q Tracon Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.66% | -23.74% | |
| Form 8-K Tracon Pharmaceuticals, For: Nov 09 | SEC filing · Form 8-K | SEC EDGAR | +5.66% | -23.74% | |
| TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +5.66% | -23.74% | |
| TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023 | Press release | GlobeNewswire | +0.35% | -2.84% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TCON section they belong to.
Where else TCON is measured.
TCON earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BASILEA PHARM AG AKT SHS (BPMUF) | 81 | 0.00% | 8% |
| MEDICAL IMAGING CORP (MEDD) | 81 | 0.00% | 32% |
| Homology Medicines, Inc. (FIXX) | 80 | -0.34% | 33% |
| Orchard Therapeutics plc - American Depositary Shares (ORTX) | 80 | +0.06% | 66% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TRACON PHARMS INC's median reaction calculated?
Every labeled TCON news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 81 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 16% of TCON's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TCON's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.